View in EDS

First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors.

Saved in:
Bibliographic Details
Title: First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors.
Authors: Yarchoan M; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland., Powderly JD; Carolina BioOncology Institute, Huntersville, North Carolina., Bastos BR; Baptist Health Miami Cancer Institute, Miami, Florida., Karasic TB; Abramson Cancer Center at the University of Pennsylvania, Philadelphia, Pennsylvania., Crysler OV; University of Michigan Rogel Cancer Center, Ann Arbor, Michigan., Munster PN; UCSF Health - UCSF Medical Center, San Francisco, California., McKean MA; Sarah Cannon Research Institute, Nashville, Tennessee., Emens LA; UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania., Saenger YM; Herbert Irving Comprehensive Cancer Center, Columbia University, New York, New York., Ged Y; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland., Stagg R; Tempest Therapeutics, Brisbane, California., Smith S; Tempest Therapeutics, Brisbane, California., Whiting CC; Tempest Therapeutics, Brisbane, California., Moon A; Tempest Therapeutics, Brisbane, California., Prasit P; Tempest Therapeutics, Brisbane, California., Jenkins Y; Tempest Therapeutics, Brisbane, California., Standifer N; Tempest Therapeutics, Brisbane, California., Dubensky TW; Tempest Therapeutics, Brisbane, California., Whiting SH; Tempest Therapeutics, Brisbane, California., Ulahannan SV; Stephenson Cancer Center of the University of Oklahoma/Sarah Cannon Research Institute, Oklahoma City, Oklahoma.
Source: Cancer research communications [Cancer Res Commun] 2024 Apr 18; Vol. 4 (4), pp. 1100-1110.
Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9918281580506676 Publication Model: Print Cited Medium: Internet ISSN: 2767-9764 (Electronic) Linking ISSN: 27679764 NLM ISO Abbreviation: Cancer Res Commun Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2767-9764
DOI:10.1158/2767-9764.CRC-24-0082